Eli Lilly and Company (NEO:ZLLY)
Canada · Delayed Price · Currency is CAD | Market Cap | 1.10T +5.0% |
| Revenue (ttm) | 89.37B +44.7% |
| Net Income | 28.30B +94.9% |
| EPS | 31.47 +96.0% |
| Shares Out | n/a |
| PE Ratio | 39.03 |
| Forward PE | 25.59 |
| Dividend | 0.02 (0.19%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 202 |
| Average Volume | 528 |
| Open | 9.50 |
| Previous Close | 9.83 |
| Day's Range | 9.50 - 9.50 |
| 52-Week Range | 9.50 - 12.05 |
| Beta | 0.43 |
| RSI | 30.71 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Pharma Offers Defensive Plays in an Uncertain Market. Charts Say Buy These 2 Stocks.
Technical indicators for Pfizer and GSK have turned bullish.
Eli Lilly Is Diving Deeper Into AI Drug Discovery With Expanded Insilico Partnership
Eli Lilly is doubling down on AI drug development with its latest deal.
Eli Lilly Ramps Up AI Ambitions With This $2.8 Billion Deal. The Stock Rises.
Lilly will obtain exclusive rights to sell treatments discovered using InSilico's Pharma.AI model.
Eli Lilly Makes $2.75 Billion Bet on AI-Powered Drug Discovery
Pharmaceutical titan Eli Lilly wants to bring medications developed with AI to market. To that end, the company has struck a $2.75 billion deal, announced Sunday (March 29), with Hong Kong-based Insil...
Eli Lilly inks $2.75B AI deal with Insilico, bets on China biotech
Global pharmaceutical major Eli Lilly has signed a drug discovery agreement with Insilico Medicine that could be worth up to $2.75 billion. The deal underscores the growing role of artificial intellig...
Eli Lilly seeks higher NHS drug prices, rebate overhaul to restart UK investment, FT reports
Eli Lilly wants the UK to regularly raise NHS drug prices and phase out a multi-billion-pound rebate scheme if it is to resume investment, its international businesses president Patrik Jonsson told ...
Eli Lilly, InSilico Strike AI Drug Discovery Deal
Hong Kong-listed InSilico sad the deal could be valued at as much as $2.75 billion.
Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery
Insilico Medicine said on Sunday it is partnering with Eli Lilly in a deal worth up to $2.75 billion, expanding an existing collaboration on AI-powered drug discovery.
Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
Hong Kong-listed Insilico Medicine has reached a deal with U.S. pharma giant Eli Lilly for AI-discovered drugs. The two companies have worked together since 2023.
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine , which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also pu...
Lilly's eczema drug shows durable long-term response in late-stage study
Eli Lilly said on Friday that its eczema drug showed durable results in a late-stage post-marketing study, such as relief from persistent itch for up to four years in patients with the skin condit...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitis
In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin clearanc...
The market for weight loss drugs is exploding and patients may have several new options in coming years—here's a look, in charts
The market for weight loss drugs is exploding and patients may have several new options in coming years.
What's Going On With Eli Lilly On Monday?
More than 80 global executives gathered in Beijing for the China Development Forum, signaling renewed corporate interest in the Chinese market despite ongoing geopolitical tensions.
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development Forum
Household names were among the more than 30 U.S. corporate executives who joined the China Development Forum in Beijing over the weekend. Fresh off a recovery in Apple iPhone sales in China, CEO Tim C...
Our Top 10 High Growth Dividend Stocks - March 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Why Eli Lilly Remains My Top Obesity Bet
Despite HSBC downgrading Eli Lilly and Company stock, it remains my favorite in the obesity treatment market. That's also because LLY's tirzepatide franchise sales grew 114.6% year-on-year to about $1...
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trial
Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight. The drug lowe...
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes
For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
Roche Holding AG has announced a major AI infrastructure expansion with Nvidia, surpassing peers in GPU deployment for drug development. RHHBY now operates over 3,500 Blackwell GPUs, positioning itsel...
Stock Of The Day: Is The Eli Lilly Selloff Over?
As you can see on the chart, in April 2025 when Eli Lilly reached the $890 level, it hit resistance. A reversal and move lower followed.
Lilly gets rare downgrade as analysts question hype over GLP-1 pills and Zepbound's cash sales
If middle-class Americans lose their jobs to AI, that could mean fewer cash sales of weight-loss drugs like Zepbound.